TrialNature medicine2025

Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.

Melissa-Rosina Pasqua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.